These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

871 related articles for article (PubMed ID: 27650132)

  • 21. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune checkpoint inhibitors in lung cancer: past, present and future.
    Seetharamu N; Budman DR; Sullivan KM
    Future Oncol; 2016 May; 12(9):1151-63. PubMed ID: 27019997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
    Marrone KA; Brahmer JR
    Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
    Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
    Chow LQ
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer.
    Helissey C; Champiat S; Soria JC
    Curr Opin Oncol; 2015 Mar; 27(2):108-17. PubMed ID: 25602683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint inhibitors in lung cancer: current status and future directions.
    Fan Y; Mao W
    Chin Clin Oncol; 2017 Apr; 6(2):17. PubMed ID: 28482670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer.
    Remon J; Besse B
    Curr Opin Oncol; 2017 Mar; 29(2):97-104. PubMed ID: 28059852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the immune system in the treatment of non-small-cell lung cancer.
    Rangachari D; Brahmer JR
    Curr Treat Options Oncol; 2013 Dec; 14(4):580-94. PubMed ID: 23934510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy.
    Sanaei MJ; Pourbagheri-Sigaroodi A; Kaveh V; Abolghasemi H; Ghaffari SH; Momeny M; Bashash D
    Eur J Pharmacol; 2021 Oct; 909():174404. PubMed ID: 34363829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.
    Lu S; Yu Y; Yang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S21-S30. PubMed ID: 30819828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469
    [No Abstract]   [Full Text] [Related]  

  • 34. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
    Kumar R; Collins D; Dolly S; McDonald F; O'Brien MER; Yap TA
    Curr Probl Cancer; 2017; 41(2):111-124. PubMed ID: 28214087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy in Lung Cancer: A New Age in Cancer Treatment.
    Corrales L; Scilla K; Caglevic C; Miller K; Oliveira J; Rolfo C
    Adv Exp Med Biol; 2018; 995():65-95. PubMed ID: 30539506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
    Villaruz LC; Socinski MA
    Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
    Flynn MJ; Larkin JMG
    Expert Opin Pharmacother; 2017 Oct; 18(14):1477-1490. PubMed ID: 28820000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.